Fibromyalgia Patients in UK at Higher Risk of Long-term Opioid Use, Analysis Finds

Fibromyalgia Patients in UK at Higher Risk of Long-term Opioid Use, Analysis Finds
3.3
(3)

People with fibromyalgia in the U.K. are 1.8 times more likely to become long-term opioid users to treat pain than the general population, according to an analysis of nearly two million people.

Overall, opioid prescriptions rose in the U.K., with 14.6% of new opioid users becoming long-term users. Researchers urged clinicians to be careful when considering high-dose opioids and to monitor patients at increased risk for long-term use.

The study, “Time trends and prescribing patterns of opioid drugs in U.K. primary care patients with non-cancer pain: A retrospective cohort study,” was published in the journal PLOS Medicine

Opioids are a broad class of pain-relieving medications that work by blocking signals between the brain and the body. They are regularly prescribed to people with chronic pain conditions such as fibromyalgia

However, opioids are also associated with serious adverse outcomes, and their use can lead to dependence and accidental overdose. 

While studies in the U.S., Canada, and several European countries have reported sharp increases in prescription opioid use for non-cancer pain, studies detailing opioid trends in the U.K. are lacking. 

As such, researchers at The University of Manchester in the U.K. analyzed the health records of 1,968,742 new opioid users who did not have cancer to understand prescribing trends from 2006 to 2017, changes in opioid dosages in the first two years of use, and risk factors as well as regional or prescriber variations for long-term use.

“No studies to our knowledge have evaluated how opioid dose/potency changes over time in U.K. patients started [on opioids] for the first time for non-cancer pain,” the scientists wrote. 

Data for eligible adults were found in the Clinical Practice Research Datalink (CPRD), a database of anonymized U.K. electronic health records. 

Classes of opioids were divided into weak opioids, including codeine and Meptid (meptazinol), moderate opioids such as tramadol and tapentadol, and strong opioids such as morphine, oxycodone, and fentanyl.

Of all new opioid users, 88.2% were started on a weak opioid, 8.5% on a moderate opioid, 2.6% on a strong opioid, and 0.7% on a combination of opioids. 

Patients ages 85 and older represented a higher proportion of those started on strong opioids (31.5%) than on weak (4.1%) or moderate opioids (3.3%). More patients with co-existing conditions and who had previously received psychotropic medications used more potent opioids.

The most commonly prescribed opioids were codeine, dihydrocodeine, and tramadol. Over the 12-year study period, codeine use increased fivefold, from 484 to 2,456 prescriptions per 10,000 individuals per year. Dihydrocodeine, tramadol, and fentanyl prescriptions increased in the first six years (2006 to 2012) and stabilized thereafter.

Oxycodone prescribing rose approximately 30-fold, from five to 169 prescriptions, while morphine use increased from 18 to 422 prescriptions per 10,000 individuals per year.

Opioid doses over two years in new users were reported as morphine milligram equivalents (MME), which is an opioid dosage equivalency to morphine. Most patients were started on low opioid doses of less than 50 MME per day, of whom 1,706,574 (88.6%) had stopped entirely by two years.

Of the 24,315 patients who started on a medium dose of 50 to 119 MME per day, 3,249 (13.4%) had escalated to a higher dose by one year, while 21,066 (86.7%) were tapered to less than 50 MME per day. Among the 1,446 patients who started at a dose of more than 200 MME per day, 656 (45.4%) continued on such high doses at six months, 434 (30%) at one year, and 270 (18.7%) at two years.

Overall, 14.6% of patients became long-term users in the first year after starting on opioids. Factors associated with a greater likelihood of long-term use included initial dose, older age, social deprivation, suicide attempts or self-harm, excess alcohol, major surgery, and use of sedatives and psychotropic agents. 

“Given the potential harms of these drugs, we think it is imperative to promote safe practices in prescribing opioids and reduce the variability we observed between … regions, practices, and prescribers,” Meghna Jani, PhD, the study’s lead author, said in a press release.

“One way to do this would be to harmonize prescribing practices across regions through future well-researched policies. The other would be developing targeted interventions in high-risk groups including areas of social deprivation and for those undergoing major surgery,” she added. 

Notably, people with fibromyalgia were 1.81 times more likely to become long-term opioid users. 

The strongest association was found in those 75 years of age and older, who were 4.6 times more likely to become long-term opioid users than people younger than 35. 

As for geographical variation, three U.K. regions — namely North West, Yorkshire and the Humber, and South West — had significantly greater proportions of long-term opioid users than the population average. 

Finally, 540 (3.5%) prescribers were associated with a significantly greater risk of long-term opioid use by their patients. While this proportion was small, said the researchers, these prescribers were associated with 3.56 times higher odds of a new opioid user becoming a long-term user compared to the population average.

“In conclusion, overall opioid prescribing has increased over 12 years, with wide variation across the U.K.,” the investigators wrote. “Clinicians should take care in prescribing high dose opioids at initiation and closely monitor those with the above individual factors for long-term use.”

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Total Posts: 27
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Latest Posts
  • opioid use
  • oxygen therapy
  • brain stimulation and pain
  • TNX-102 SL trial enrollment

How useful was this post?

Click on a star to rate it!

Average rating 3.3 / 5. Vote count: 3

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?